Skip to content

BIOCLIN

Active Public limited companyfounded 1976active for 50 yearsTroonstraat 60, 8400 OstendKBO/BCE: BE 0416.553.335

Lifetime

24 annual accounts with figures on one time axis, 49 filings since 1977
peak of €143,439 in 2005
€97,820▼ 2.5%
lowest -€25,492 in 2016
€8,400▼ 70.7%
peak of €287,066 in 2023
€274,684▼ 2.7%
€314,432▼ 6.3%
peak of 2.5 FTE in 2002
0.5 FTE▲ 25.0%
Board3 names since 2009
1 director
Owners2 names in the annual accounts
50% and 1 other
Documentsfilings and deeds
19-06-202642 days before the deadline
2025abbreviated format
Result from €28,717 to €8,400Staff from 0.4 FTE to 0.5 FTE

Key points

from the 2025 annual accounts

Equity

€274,684 ▼ 2.7%

BIOCLIN has made a profit without a break since 2021.

Filings

49 annual accounts since 1977
AprilJune31 JulyOctober1980199520102025

Two of the last ten came late. The 2017 accounts came in latest, 30 days after the end of the period.

Board

2 joined

2 directors joined, the latest on 01-02-2026. 3 are in office now.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,054 companies had the same profile as BIOCLIN has now. Each dot stands for 43 companies, two years later.

94.3%
were still trading
5.0%
stopped another way
0.6%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,054 companies, not a prediction for BIOCLIN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director,
Director,
Director
  • 50%score equity €137,100 (2025) · annual accounts 2025 of
  • 49.84%score equity €553,324 (2025) · annual accounts 30-06-2025 of

Shares in 1 company,

Board & ownership

Recent changes

3 directors reappointed and act as permanent representatives · (managing director), and · General meeting of 16-06-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0416553335
Registered office moved within Ostend The registered office moved from Troonstraat 99 bus 1 te 8400 Oostende to Troonstraat 60 te 8400 Oostende · “Het oprichten, overnemen en uitbaten van een apotheek of apotheken met alle hieronder inbegrepen activiteiten…” (deed in Dutch) · Registered office in the articles: Troonstraat 60, 8400 Oostende · Gazette deed
2 directors appointed, 2 resignations changes role from director to managing director · and resign · and appointed · General meeting of 01-02-2020 · Gazette deed
All 65 events

Comparable companies

same main activity, similar in size and age
Company
BIOCLIN Ostend €623,434 €97,820 44.1% 0.5
APOTHEEK JULIE DEBAERE Ypres €599,022 €98,975 42.9% 0.8
APOTHEEK ORSCAMP Oostkamp €623,563 €84,508 59.9% 0.4
APOTHEEK REYNAERT Bruges €743,944 €75,805 39.8% 0.5
Apotheek Gheysens Julie Kortrijk €620,116 €118,676 82.3% 1
AUDOPHARMA De Panne €483,083 €114,780 48.3% 0.9
APOTHEEK VREYS Geel €754,200 €134,475 44.0% 0.4

These companies have the same main activity as BIOCLIN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €483,000 and €754,000, founded between 1974 and 1987.

Official details

Source: KBO
Status
Active since 30-10-1976Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2024
Establishment unit
2.017.208.2388400 Ostend, since 01-02-1980
Financial year end
31 December
Peppol
Reachable since 24-11-2023
Company details

Annual accounts 2025

≈ €480,000estimated
€623,434▼ 5.1%
Employeeson 31-12-2025
1=
Filing
Filed on 19-06-2026, 42 days before the end of the filing period
Financials

Insights on BIOCLIN

BIOCLIN files the abbreviated format. That format states no turnover. The gross margin rose from €85,384 in 2002 to €97,820 in 2025.

The balance sheet grew most in 2022 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BIOCLIN

What is the company number of BIOCLIN?
The company number of BIOCLIN is 0416.553.335. The VAT number is the same number with BE in front: BE 0416.553.335.
Where is BIOCLIN based?
The registered office is at Troonstraat 60, 8400 Ostend.Company details
What does BIOCLIN do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of BIOCLIN?
BIOCLIN is a public limited company (NV).
When was BIOCLIN founded?
BIOCLIN was founded on 30-10-1976.
Is BIOCLIN still active?
Yes, BIOCLIN is an active enterprise in the KBO register.
How many employees does BIOCLIN have?
BIOCLIN had an average of 0.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does BIOCLIN fall under?
In its 2024 annual accounts, BIOCLIN states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of BIOCLIN?
The turnover in financial year 2025 is about €480,000. This figure is estimated from the gross margin of €97,820 and 78 comparable companies (NACE 477). It probably lies between €240,000 and €690,000.
Is BIOCLIN profitable?
In financial year 2025, BIOCLIN made a profit of €8,400.
Where can I find the annual accounts of BIOCLIN?
BIOCLIN filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BIOCLIN due?
BIOCLIN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.